Clinical decision-making in perinatology involves trade-offs between two intricately related individuals -mother and fetus. Decision-making in perinatology is challenging due to competing interests of the mother and the fetus. Although decision analytic methods are increasingly used to develop processes for clinical and cost-effectiveness analyses in perinatology, there are no guidelines on the conduct and reporting of decision analysis studies that takes into account the complexities of the mother-fetus dyad. This article describes the basics of decision analysis and highlights areas that require special consideration in the perinatal context. It emphasizes the importance of obtaining patient preferences related to combined maternal-fetal health states, stresses the relevance of both maternal and offspring health outcomes over appropriate time horizons, and explains challenges around the use of qualityadjusted life years as an outcome measure in perinatology. It also provides insight into the complexities of dyad status in clinical and cost-effectiveness analyses in perinatology.
Introduction
The perinatal period extends from the period of viability (defined variably as between 20 and 28 weeks) until 4 weeks after birth and involves two individuals, the mother-fetus dyad, wherein the health of one is contingent on that of the other. Often the mother and the fetus have competing interests requiring medical decisions to be made in favor of one, and at the expense of the other. Examples of this include the need to withhold life-saving medications from the mother due to the risk of fetal teratogenicity, or prolongation of pregnancies complicated by serious maternal disease to reduce complications of prematurity. The competing interests of mother and fetus render medical decision-making in perinatology extremely complex. Since the fetus cannot make decisions regarding its own wellbeing, this responsibility has traditionally rested with the healthcare provider, often, but not always, in consultation with pregnant women. While pregnant women desire to participate in making decisions involving their health and that of their unborn fetuses (1), involving pregnant women in medical decision-making can become overwhelming as the number of management strategies and possible outcomes increases. This is true not only at the individual level, but even more so at a population level.
Clinical decision analysis (CDA) is a methodology where empirical data including patient preferences are acknowledged, quantified and integrated into medical decision-making (2) . It is commonly used to support clinical and policy decisions, especially where head-tohead comparisons are lacking (3) . It is now widely used to inform clinical and policy decisions in many clinical disciplines, and guidelines provide direction on the conduct and reporting of CDA and economic evaluation studies in healthcare (4) (5) (6) . CDA is especially suited to support complex decision-making in perinatology where one must consider a number of management strategies and a multitude of outcomes involving the mother-fetus dyad that often have competing interests. It is therefore not surprising that there has been a rapid increase in publication of CDA studies in perinatology in the past few years ( Figure 1 ). Although the interest in using CDA to answer clinical questions in perinatology is evident from the large number of published studies and conference abstracts (Figure 2 ), the uptake of CDA studies in perinatology has not been global. A systematic review of CDA and model-based economic evaluation studies in perinatology identified 71 eligible publications, of which only one described management in a low-income country (Malawi) and three in upper-middle income countries (Brazil and Bulgaria), whereas 67 (94%) were conducted in high-income countries, most notably the USA (51, 72%) ( Figure 3 ) (7).
In 2012, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and Society for Medical Decision Making (SMDM) published recommendations for best practices in decision modeling (8) (9) (10) (11) (12) (13) (14) , followed by recommendations for economic evaluation by the second panel on cost-effectiveness in health and medicine in 2016 (6) . This article will provide an overview of these recommendations and discuss special considerations with regard to perinatology, using the example of choosing the optimal anticoagulant (blood thinner) in pregnant women with mechanical heart valves.
A decision problem: choosing the optimal anticoagulant (blood thinner) in pregnant women with mechanical heart valves In pregnant women with mechanical heart valves, four strategies for anticoagulation could be considered in contemporary practice -vitamin-K antagonists, low molecular weight heparin (LMWH), unfractionated heparin (UFH) or sequential treatment (LMWH or UFH in the first trimester and peripartum period and vitamin-K antagonists in the second and third trimesters). There is Number of publications by study type Year of publication no consensus on the optimal management strategy and each of these strategies could result in a number of shortand long-term effects on both mother and offspring.
Before embarking on CDA in perinatology, it is imperative to determine whether the research question is amenable to CDA and that CDA is the best methodology to answer the question. A good research question for CDA is one in which head-to-head comparisons need to be made between two or more possible strategies involving a large number of possible outcomes, which cannot be adequately answered by the conduct of randomized controlled trials or observational studies. In the anticoagulant example, randomized controlled trials comparing four strategies are difficult to undertake, observational studies draw conflicting conclusions depending on which outcomes are considered, and equipoise of maternal and offspring wellbeing is unlikely (15) . CDA has the ability to make head-to-head comparisons between all four strategies based on a variety of maternal and offspring outcomes, while incorporating patient preferences for these 
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Canada, 1 outcomes, and could provide a more holistic approach to determining the optimal anticoagulant for these women.
In this example, if we were only to consider the mother, vitamin-K antagonists that are most effective at preventing maternal blood clots and death, would emerge the optimal strategy. Conversely, if we were only to consider the fetus, LMWH that does not cross the placenta, thereby resulting in no fetal adverse effects, would be the preferred strategy. International societies such as the American Heart Association/American College of Cardiology and the European Society of Cardiology unanimously endorse the use of vitamin-K antagonists, and discourage the use of LMWH (16, 17) , underscoring how healthcare providers, researchers and policy makers tend to favor the mother when difficult choices must be made between maternal and fetal health. Considering the health of both mother and baby, whose interests often compete, is one of the features that make CDA studies in perinatology unique.
Considerations specific to perinatology
Key considerations in the conduct and reporting of CDA studies specific to perinatology, based on the 2012 ISPOR-SMDM recommendations (8, 9) , are summarized in Table 1 and described below.
Choice of model
Translating the decision problem into a CDA model should involve an explicit and clearly outlined process to ensure that the model reflects current theory of the disease history. Different model types have been described (9-13), and although several types of models could adequately answer a decision problem in perinatology, some problems are more naturally represented in certain modeling types than in others. In general, while simplicity is desirable for transparency, ease of validation and description, the model should be sufficiently complex to answer the question at a level of detail consistent with the problem being modeled, and to preserve face validity to clinical experts. We will use a simple decision tree to illustrate the effects of various anticoagulants in our example. The structure and components of a decision tree are explained in Figure 4 .
Time horizon
In order to make a fair comparison of strategies, the consideration of an appropriate time-horizon is vital. Modeling over a patient's lifetime usually requires extrapolating well beyond available data, since randomized controlled trials and observational studies rarely cover such long periods. Thus, short-term outcomes may be based on primary data, whereas long-term effects are often extrapolated. Time horizons considered by CDA studies in perinatology include "pregnancy and delivery", "pregnancy and the postpartum period" (variably, 6 weeks to 1 year), "the mother's reproductive life" and maternal lifetime for maternal outcomes and anything between a few months after birth to the entire lifetime for offspring outcomes (7, 18) . Caution must be exercised while considering short time horizons such as pregnancy and delivery alone, as the implications of some interventions and outcomes extend beyond that time horizon. For example, heavy bleeding resulting in the removal of a woman's uterus affects the rest of her reproductive life, and a blood clot resulting in stroke, has lifelong implications for the woman and her family. Similarly, an offspring outcome such as cerebral palsy or permanent physical and mental handicap has lifetime consequences for the offspring, which will not be captured by a shorter time horizon considering only a few years after birth. CDA studies in perinatology must include the appropriate maternal and offspring time horizons with appropriate justification for the choice.
Parameterizing the model and identifying key uncertainties
As mentioned in Table 1 , the model needs to be parameterized by at least two types of data. (1) The chance (probability) of each event (health outcome) occurring and (2) the value (utility or costs) of each event. There are some considerations specific to these parameters with regard to perinatology. Where possible, probabilities should be obtained from meta-analysis, network metaanalysis (10), health administrative data or literature reviews using weighted probabilities (based on individual study size) if multiple sources are used. The source and manner in which the probabilities were obtained must be clearly stated. For our example, probabilities have been obtained from a systematic review and meta-analysis on the topic (19) . However, in perinatology, it is often not possible to find probabilities from these sources, in which case researchers might need to use 'subjective probabilities' that involve making an educated guess based on a judgement or strength of belief. As this is subject to three major types of bias -representativeness bias, availability bias and anchoring bias -it has been suggested that the use of subjective probabilities is restricted only to situations where no published data are available and, when used, consensus should be obtained using the Delphi method involving a panel of experts (20) . 
General recommendations
Specific recommendation for perinatology
Conceptualizing the problem
The research question Ensure that the question is amenable to CDA and that CDA is the best methodology to answer the question.
Nature of the problem • Present a clear, written statement of the decision problem, as well as scope and objective of the model • Consult with subject experts and stakeholders, to ensure that the model represents the disease processes appropriately and addresses the decision problem adequately.
Target population Define clearly in terms of geography, patient characteristics and disease stage.
Include both mother and fetus and, if either is excluded, provide justification.
Project objectives
State whether the objective is to guide clinical practice, inform a funding decision, optimize scare resources or guide public health practice, due to implications on model structure, data requirements, analytic strategy and reporting.
Conceptualizing the model
Choice of model Clinical problems can often be represented in any type of model, although some methods are better suited to particular problem types. Appropriateness of model should be decided based on whether the model will represent individuals or groups, whether there are interactions among individuals, the time horizon, whether time is continuous or discrete, whether events occur more than once and whether resource constraints need to be considered.
Strategies/Comparators Model all interventions and their variations, while including standard care and the option of "no intervention".
Health outcomes
Include all features of the disease and its outcomes, including where data may be poor or unavailable.
Include all relevant maternal and fetal outcomes, or provide justification for exclusion.
Analytic perspective If analysis is not performed from at least two perspectives -healthcare system and society -provide justification.
Time horizon Use appropriate time horizons Include entire lifetime of both mother and offspring in all instances. If not, provide justification.
Populating the model Probabilities
• Use estimates from meta-analysis and network meta-analyses.
• When obtained from multiple sources, use weighted probabilities.
• When using subjective probabilities, consider Delphi methodology, involving experts.
Utilities
• May be obtained by a variety of direct and indirect valuation methods.
• Obtain preferences from the general public where possible.
• Standard gamble is probably the most appropriate direct valuation method in perinatology.
• Involve pregnant women with the condition.
• Consider obtaining utilities through shared interviews with partner/family member
Costs
• Estimate costs, not charges • All costs should be in equivalent units
• Discount costs at a rate of 3% per annum
• Consider spill over effects on family and society
Comparing strategies
Event rates Often used as indicative of better health Avoid, as inverse relation between maternal and fetal event rates would result in biased conclusions depending on which event rates are chosen.
Expected utilities Includes patient-preferences but not quantity of life May be used to compare strategies in perinatology Quality-adjusted life years (QALYs)
Allows consideration of a variety of clinical outcomes, patient-preferences for those outcomes as well as the quantity of life.
• Avoid summing up/multiplying maternal and fetal QALYs.
• Consider separate analyses from maternal and offspring perspective, bearing in mind that results may be conflicting.
• Compare strategies based on maternal QALYs that take into account utilities for combined maternal-fetal health states, thereby capturing the quality and quantity of life of both individuals from the perspective of the mother.
CDA, clinical decision analysis; QALY, quality-adjusted life years. possible outcome) to one (perfect health or the best possible outcome). Just as it is important to discuss all outcomes with patients and choose the optimal strategy based on patient preferences in the clinical setting (15) , it is imperative to include not only the probabilities of health outcomes relating to maternal and fetal health, but also the preferences (utilities) assigned to these outcomes when conducting CDA in perinatology (4). Obtaining utilities in perinatology can be challenging because of the lack of consensus in two vital areas:
Utilities

Methods for obtaining utilities
Various methods of eliciting utilities have been described, the most common being direct valuation methods such as the visual analog scale (a simple rating scale with values ranging from zero for the worst health state to 100 for perfect health), time trade-off (where respondents trade time off the end of their lives in the current health state in order to live fewer years in perfect health) and the standard gamble (where respondents choose between the certainty of remaining in the current health state or taking a hypothetical treatment that has an X% chance of immediate death and a 100 -X% chance of full health). Although the visual analog scale is simple to understand and use, it generates values with wide confidence intervals that are not easily reproducible (21) . The time trade-off method that requires trading time off the end of one's life in order to spend fewer years in the best possible health state, works effectively for some populations such as those with cancer or in the elderly; however, this is not an easy concept to understand for a woman in the reproductive age group (21) . An alternate method of asking pregnant women to trade a proportion of time off a single year (22) is equally challenging because they are still expected to trade time off their own lives in the future, for health consequences affecting them and their fetuses in the present. The standard gamble in this population has been found to be easily understood and generate the narrowest confidence limits around estimates (21) . When the three methods are compared, wide variations in utilities are obtained. Based on our experience to date, the standard gamble, which is the reference standard for measuring utilities, seems to be the preferred direct method of eliciting utilities in perinatology (21, 22) . The use of indirect methods such as generic preferencebased (for example EQ-5D) and non-preference-based (SF-36) measures of health-related quality of life, which have algorithms to transform them into utilities, and other methods such as measuring utilities in monetary terms and using discrete choice experiments is beyond the scope of this paper.
The role of partners and family members
Utilities are ideally obtained from the general public (6) or patients with the condition, but in perinatology, utilities for conditions affecting the mother-fetus dyad have been variably obtained from the pregnant woman, both parents, healthcare providers and the general public. In perinatology, the role of the pregnant woman's partner in providing utilities is undetermined. It can be argued that in North America, where the fetus until delivery is not regarded as an independent entity but instead part of the woman's body, the woman should solely be allowed to make decisions on behalf of them both. However, the consequences of the decisions she makes would be borne by the partner/ family in due course, making a case for the partner's involvement in the elicitation of utilities. When we elicited utilities from pregnant women and their family members involved in decision-making, we found that utilities differ markedly based on the person interviewed, and that utilities obtained from shared interviews were closer to those of family members rather than of pregnant women (21) . While the reasons for these differences are yet to be determined, consideration should be given to involving partners/family in eliciting utilities in perinatology.
Outcomes
Clinical outcomes. Decision-making in perinatology involves trade-offs between maternal and fetal health. It is important that health outcomes for both the mother and the fetus are considered in all analyses, to ensure that impartial conclusions are drawn. Rather than recording maternal and fetal health outcomes separately, consideration should be given to the use of health states that involve combined maternal-fetal outcomes. In our example, maternal outcomes include death, blood clot and no complications, and fetal outcomes include death, congenital malformations and no complications. There are therefore seven possible combined maternal-fetal health states that are represented in gray boxes in Figure 3 .
Comparing strategies based on clinical outcomes. In CDA, where only clinical outcomes are considered and not costs, strategies are compared based on clinical outcomes (rates of clinically defined states or events), expected utilities (weighted average of the utilities of its possible outcomes) (22) , or health indices that characterize health using a vector composed of separate measures of quality and quantity of life, for example quality-adjusted life years (QALYs). Event rates are usually selected in medicine because they are associated with better health. However, they do not take into account the preferences of patients for these health states and do not always include long-term or final outcomes (4). In perinatology, where event rates of maternal and fetal health outcomes are almost always inversely related, comparing strategies based on event rates would provide a biased result. In our example, the use of event rates such as maternal death, blood clots, fetal death and congenital malformation would produce results no different from those obtained from the systematic review (19) -that vitamin-K antagonists are better for the mother and LMWH better for the fetus. The use of expected utilities allows the incorporation of patient preferences for combined maternal-fetal health states arising from the use of anticoagulants in pregnancy (21) . However, this does not take into account the "quantity of life" (life expectancy) of both mother and offspring. Using QALYs as outcome measures allows consideration of a variety of clinical outcomes, patient-preferences for those outcomes as well as the quantity of life, and are therefore widely used in CDA. However, their use in perinatology is not straightforward (18) . The relatively longer life expectancy of the offspring compared with the mother, would mean that the offspring's QALYs would influence the resultant QALYs to a disproportionately greater extent (23) . An alternate method of using QALYs in perinatology could be to compare strategies based on maternal QALYs that take into account utilities for combined maternal-fetal health states, thereby capturing the quality and quantity of life of both individuals from the perspective of the mother and/or partner/family member.
Costs. There are no specific considerations in perinatology with regard to costs, except that lifetime costs for both mother and offspring should be considered wherever possible, and a justification provided when this is not done. The spillover effect on caregivers and family members must be taken into account where possible, by the inclusion of a societal perspective in the cost analysis (6) . In addition, studies should attempt to assign QALYs for pregnancy-related outcomes and avoid reporting costs per intermediate outcomes as is often done (18) .
Analytic perspectives
For decision problems in healthcare, commonly considered perspectives are those of the patient, third-party payer or insurer/healthcare system and society. CDA models, especially those supporting medical decisionmaking as opposed to economic evaluations informing policy decisions, often do not explicitly state the analytic perspective, but generally include health outcomes accruing to patients with the disease of interest. In perinatology, the consequences of decisions made by the pregnant woman, in addition to affecting her own health outcomes and those of her baby, also influence the quality of life of her partner, her other children and extended family, and incur costs to the healthcare system and society at large. The second panel on cost-effectiveness in health and medicine has recently recommended that analysis should be performed from at least two perspectives, that of the healthcare system and society, the latter of which incorporates spillover costs and benefits to all members of society (6) . The choice of perspective has a major impact on a study's findings and hence the analytic perspective should be clearly stated and defined; outcomes modeled should be consistent with the perspective, and analyses that do not include societal and healthcare system perspectives should report and justify this decision (9) .
Other steps in the conduct of CDA involve performing sensitivity analyses wherein each of the key probabilities, utilities and costs are varied within a range of reasonable uncertainty to test the robustness of the conclusion, validating the model to judge its accuracy in making relevant predictions, and ensuring transparency to enhance trust and confidence that is critical to the success of CDA. Sensitivity analysis is a vital feature of CDA studies, as study results can be sensitive to the values assigned to key parameters and the model structure. The quality of sensitivity analysis assessing parameter uncertainty is determined on the basis of how the uncertain parameters were identified, how the plausible ranges for the parameters were specified, and whether an appropriate form of sensitivity analysis was used. Deterministic sensitivity analysis was commonly used in CDA and economic evaluation studies, but probabilistic sensitivity analysis is now widely used and recommended (24) . The advantage of this approach is that it is possible to characterize the combined effect of all parameter uncertainty in the analysis. There are no specific differences for these steps with regard to perinatology and researchers are encouraged to follow published recommendations (6, 14) .
Conclusions
Clinicians, researchers and policy makers are increasingly relying on CDA to determine optimal management strategies in perinatology. However, it is important to recognize the unique challenges posed by the mother-fetus dyad in the conduct of these studies. When conducting CDA studies in perinatology, is important to consider maternal and offspring outcomes across their lifespans, obtain utilities that adequately capture maternal-offspring health states, consider preferences of partners/family members in addition to those of the pregnant woman, acknowledge the challenges to the use of QALYs, and perform economic evaluation from the perspective of the healthcare system and society.
